Belite Bio Reports Q1 2025 Results and Corporate Update
Ticker: BLTE · Form: 6-K · Filed: May 14, 2025 · CIK: 1889109
| Field | Detail |
|---|---|
| Company | Belite Bio, INC (BLTE) |
| Form Type | 6-K |
| Filed Date | May 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, corporate-update, sec-filing
TL;DR
Belite Bio dropped Q1 2025 earnings & update on May 13th. Check the 6-K.
AI Summary
Belite Bio, Inc. announced its first-quarter 2025 financial results and provided a corporate update via a press release on May 13, 2025. The company is a foreign private issuer filing a Form 6-K report with the SEC.
Why It Matters
This filing provides investors with the latest financial performance and strategic developments for Belite Bio, Inc., crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial results filing (6-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- Belite Bio, Inc. (company) — Registrant
- May 13, 2025 (date) — Date of press release
- 12750 High Bluff Drive Suite 475, San Diego, CA 92130 (address) — Principal executive office
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report Belite Bio, Inc.'s first-quarter 2025 financial results and provide a corporate update, as detailed in their press release dated May 13, 2025.
When did Belite Bio, Inc. issue the press release mentioned in the filing?
Belite Bio, Inc. issued the press release on May 13, 2025.
What is the Commission File Number for Belite Bio, Inc.?
The Commission File Number for Belite Bio, Inc. is 001-41359.
Where are Belite Bio, Inc.'s principal executive offices located?
Belite Bio, Inc.'s principal executive offices are located at 12750 High Bluff Drive Suite 475, San Diego, CA 92130.
What type of report is this filing, and what does it signify?
This is a Form 6-K, which is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15b-16 of the Securities Exchange Act of 1934, used to disseminate information to the public.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 14, 2025 regarding BELITE BIO, INC (BLTE).